Ifo-Cell N (Ifosfamide)

Ifosfamide is converted in the body to an active metabolite that alkylates DNA, creating cross‑links that block DNA replication and transcription. This damage triggers programmed cell death, preferentially affecting rapidly dividing cancer cells.

The dose of Ifo-Cell N is individualized by the prescribing oncologist based on tumour type, patient weight, renal function and treatment protocol. Exact dosing schedules are determined by clinical guidelines and the treating physician.

Safety data for ifosfamide in pregnancy and lactation are limited. The drug is generally avoided during pregnancy because of potential fetal toxicity, and breastfeeding is not recommended while receiving treatment.

To order Ifo-Cell N, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ifosfamide belongs to the nitrogen‑mustard alkylating class, similar to cyclophosphamide. Compared with cyclophosphamide, ifosfamide often shows greater activity against certain sarcomas and testicular tumours but may have a higher risk of uro‑toxicity, requiring routine mesna co‑administration.

Ifo-Cell N should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. Use aseptic technique when preparing the intravenous infusion, and discard any solution that appears discoloured or contaminated.

Ifo-Cell N is given as an intravenous infusion, typically over 1–3 hours, depending on the protocol. It is commonly administered together with mesna to prevent haemorrhagic cystitis, and infusion rates are adjusted according to patient tolerance and renal function.

Serious risks include nephrotoxicity, encephalopathy, severe myelosuppression leading to infection or bleeding, secondary leukaemia, and cardiotoxicity. Patients should be monitored closely for changes in kidney function, neurological status and blood counts throughout treatment.

Ifo-Cell N is contraindicated in patients with known hypersensitivity to ifosfamide or its excipients, severe renal impairment, uncontrolled infections, and in pregnant women unless the therapeutic benefit outweighs the risk. Caution is also advised for individuals with pre‑existing cardiac disease.